Long-term follow-up of monoclonal gammopathy of undetermined significance

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

BACKGROUND: Monoclonal gammopathy of undetermined significance (MGUS) occurs in approximately 3% of persons 50 years of age or older. METHODS: We studied 1384 patients who were residing in southeastern Minnesota and in whom MGUS was diagnosed at the Mayo Clinic in the period from 1960 through 1994; the median follow-up was 34.1 years (range, 0.0 to 43.6). The primary end point was progression to multiple myeloma or another plasma-cell or lymphoid disorder. RESULTS: During 14,130 person-years of follow-up, MGUS progressed in 147 patients (11%), a rate that was 6.5 times (95% confidence interval [CI], 5.5 to 7.7) as high as the rate in the control population. The risk of progression without accounting for death due to competing causes was 10% at 10 years, 18% at 20 years, 28% at 30 years, 36% at 35 years, and 36% at 40 years. Among patients with IgM MGUS, the presence of two adverse risk factors - namely, an abnormal serum free light-chain ratio (ratio of kappa to lambda free light chains) and a high serum monoclonal protein (M protein) level (≥1.5 g per deciliter) - was associated with a risk of progression at 20 years of 55%, as compared with 41% among patients who had one adverse risk factor and 19% among patients who had neither risk factor. Among patients with non-IgM MGUS, the risk of progression at 20 years was 30% among those who had the two risk factors, 20% among those who had one risk factor, and 7% among those who had neither risk factor. Patients with MGUS had shorter survival than was expected in the control population of Minnesota residents of matched age and sex (median, 8.1 vs. 12.4 years; P<0.001). CONCLUSIONS: Significant differences were noted in the risk of progression between patients with IgM MGUS and those with non-IgM MGUS. Overall survival was shorter among patients with MGUS than was expected in a matched control population.

Original languageEnglish (US)
Pages (from-to)241-249
Number of pages9
JournalNew England Journal of Medicine
Volume378
Issue number3
DOIs
StatePublished - Jan 18 2018

Fingerprint

Monoclonal Gammopathy of Undetermined Significance
Immunoglobulin M
Population
Light
Survival
Plasma Cells
Multiple Myeloma
Blood Proteins
Confidence Intervals

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Long-term follow-up of monoclonal gammopathy of undetermined significance. / Kyle, Robert A.; Larson, Dirk R.; Therneau, Terry M; Dispenzieri, Angela; Kumar, Shaji K; Cerhan, James R; Rajkumar, S Vincent.

In: New England Journal of Medicine, Vol. 378, No. 3, 18.01.2018, p. 241-249.

Research output: Contribution to journalArticle

@article{d5282f564f804c49929a7ef560ab60cb,
title = "Long-term follow-up of monoclonal gammopathy of undetermined significance",
abstract = "BACKGROUND: Monoclonal gammopathy of undetermined significance (MGUS) occurs in approximately 3{\%} of persons 50 years of age or older. METHODS: We studied 1384 patients who were residing in southeastern Minnesota and in whom MGUS was diagnosed at the Mayo Clinic in the period from 1960 through 1994; the median follow-up was 34.1 years (range, 0.0 to 43.6). The primary end point was progression to multiple myeloma or another plasma-cell or lymphoid disorder. RESULTS: During 14,130 person-years of follow-up, MGUS progressed in 147 patients (11{\%}), a rate that was 6.5 times (95{\%} confidence interval [CI], 5.5 to 7.7) as high as the rate in the control population. The risk of progression without accounting for death due to competing causes was 10{\%} at 10 years, 18{\%} at 20 years, 28{\%} at 30 years, 36{\%} at 35 years, and 36{\%} at 40 years. Among patients with IgM MGUS, the presence of two adverse risk factors - namely, an abnormal serum free light-chain ratio (ratio of kappa to lambda free light chains) and a high serum monoclonal protein (M protein) level (≥1.5 g per deciliter) - was associated with a risk of progression at 20 years of 55{\%}, as compared with 41{\%} among patients who had one adverse risk factor and 19{\%} among patients who had neither risk factor. Among patients with non-IgM MGUS, the risk of progression at 20 years was 30{\%} among those who had the two risk factors, 20{\%} among those who had one risk factor, and 7{\%} among those who had neither risk factor. Patients with MGUS had shorter survival than was expected in the control population of Minnesota residents of matched age and sex (median, 8.1 vs. 12.4 years; P<0.001). CONCLUSIONS: Significant differences were noted in the risk of progression between patients with IgM MGUS and those with non-IgM MGUS. Overall survival was shorter among patients with MGUS than was expected in a matched control population.",
author = "Kyle, {Robert A.} and Larson, {Dirk R.} and Therneau, {Terry M} and Angela Dispenzieri and Kumar, {Shaji K} and Cerhan, {James R} and Rajkumar, {S Vincent}",
year = "2018",
month = "1",
day = "18",
doi = "10.1056/NEJMoa1709974",
language = "English (US)",
volume = "378",
pages = "241--249",
journal = "New England Journal of Medicine",
issn = "1533-4406",
publisher = "Massachussetts Medical Society",
number = "3",

}

TY - JOUR

T1 - Long-term follow-up of monoclonal gammopathy of undetermined significance

AU - Kyle, Robert A.

AU - Larson, Dirk R.

AU - Therneau, Terry M

AU - Dispenzieri, Angela

AU - Kumar, Shaji K

AU - Cerhan, James R

AU - Rajkumar, S Vincent

PY - 2018/1/18

Y1 - 2018/1/18

N2 - BACKGROUND: Monoclonal gammopathy of undetermined significance (MGUS) occurs in approximately 3% of persons 50 years of age or older. METHODS: We studied 1384 patients who were residing in southeastern Minnesota and in whom MGUS was diagnosed at the Mayo Clinic in the period from 1960 through 1994; the median follow-up was 34.1 years (range, 0.0 to 43.6). The primary end point was progression to multiple myeloma or another plasma-cell or lymphoid disorder. RESULTS: During 14,130 person-years of follow-up, MGUS progressed in 147 patients (11%), a rate that was 6.5 times (95% confidence interval [CI], 5.5 to 7.7) as high as the rate in the control population. The risk of progression without accounting for death due to competing causes was 10% at 10 years, 18% at 20 years, 28% at 30 years, 36% at 35 years, and 36% at 40 years. Among patients with IgM MGUS, the presence of two adverse risk factors - namely, an abnormal serum free light-chain ratio (ratio of kappa to lambda free light chains) and a high serum monoclonal protein (M protein) level (≥1.5 g per deciliter) - was associated with a risk of progression at 20 years of 55%, as compared with 41% among patients who had one adverse risk factor and 19% among patients who had neither risk factor. Among patients with non-IgM MGUS, the risk of progression at 20 years was 30% among those who had the two risk factors, 20% among those who had one risk factor, and 7% among those who had neither risk factor. Patients with MGUS had shorter survival than was expected in the control population of Minnesota residents of matched age and sex (median, 8.1 vs. 12.4 years; P<0.001). CONCLUSIONS: Significant differences were noted in the risk of progression between patients with IgM MGUS and those with non-IgM MGUS. Overall survival was shorter among patients with MGUS than was expected in a matched control population.

AB - BACKGROUND: Monoclonal gammopathy of undetermined significance (MGUS) occurs in approximately 3% of persons 50 years of age or older. METHODS: We studied 1384 patients who were residing in southeastern Minnesota and in whom MGUS was diagnosed at the Mayo Clinic in the period from 1960 through 1994; the median follow-up was 34.1 years (range, 0.0 to 43.6). The primary end point was progression to multiple myeloma or another plasma-cell or lymphoid disorder. RESULTS: During 14,130 person-years of follow-up, MGUS progressed in 147 patients (11%), a rate that was 6.5 times (95% confidence interval [CI], 5.5 to 7.7) as high as the rate in the control population. The risk of progression without accounting for death due to competing causes was 10% at 10 years, 18% at 20 years, 28% at 30 years, 36% at 35 years, and 36% at 40 years. Among patients with IgM MGUS, the presence of two adverse risk factors - namely, an abnormal serum free light-chain ratio (ratio of kappa to lambda free light chains) and a high serum monoclonal protein (M protein) level (≥1.5 g per deciliter) - was associated with a risk of progression at 20 years of 55%, as compared with 41% among patients who had one adverse risk factor and 19% among patients who had neither risk factor. Among patients with non-IgM MGUS, the risk of progression at 20 years was 30% among those who had the two risk factors, 20% among those who had one risk factor, and 7% among those who had neither risk factor. Patients with MGUS had shorter survival than was expected in the control population of Minnesota residents of matched age and sex (median, 8.1 vs. 12.4 years; P<0.001). CONCLUSIONS: Significant differences were noted in the risk of progression between patients with IgM MGUS and those with non-IgM MGUS. Overall survival was shorter among patients with MGUS than was expected in a matched control population.

UR - http://www.scopus.com/inward/record.url?scp=85040943597&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85040943597&partnerID=8YFLogxK

U2 - 10.1056/NEJMoa1709974

DO - 10.1056/NEJMoa1709974

M3 - Article

VL - 378

SP - 241

EP - 249

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 1533-4406

IS - 3

ER -